# Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

> **NCT02637934** · PHASE1 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 35 (estimated)

## Conditions studied

- Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

## Interventions

- **DRUG:** [18F]FluorThanatrace
- **RADIATION:** PET/CT imaging sessions

## Key facts

- **NCT ID:** NCT02637934
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-01-14
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637934, "Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02637934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*